Benzinga··Vandana SinghCogent Biosciences Stock Surges on FDA Acceptance of Bezuclastinib Application
$COGT surges 5.24% after FDA accepts bezuclastinib NDA for Non-Advanced Systemic Mastocytosis, with decision expected by December 2026.
COGTFDA approvalbiotech